Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?

[1]  H. Ford,et al.  Cellular Plasticity in Breast Cancer Progression and Therapy , 2020, Frontiers in Molecular Biosciences.

[2]  J. Zhai,et al.  Expression signatures and roles of microRNAs in inflammatory breast cancer , 2019, Cancer Cell International.

[3]  S. Vacher,et al.  Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer , 2018, Breast Cancer Research.

[4]  A. Angelucci,et al.  Non-conventional role of haemoglobin beta in breast malignancy , 2017, British Journal of Cancer.

[5]  W. Woodward,et al.  Inflammatory breast cancer: a model for investigating cluster-based dissemination , 2017, npj Breast Cancer.

[6]  M. Cristofanilli,et al.  Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients , 2017, Breast Cancer Research and Treatment.

[7]  Sridhar Ramaswamy,et al.  Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination , 2017, Nature Communications.

[8]  C. Ghigna,et al.  EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression , 2017, Molecular Cancer.

[9]  F. Bertucci,et al.  Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[10]  V. Velculescu,et al.  Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors , 2016, Molecular Cancer Therapeutics.

[11]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[12]  P. Stephens,et al.  Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations , 2015, Breast Cancer Research and Treatment.

[13]  F. Bertucci,et al.  Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease , 2015, Molecular oncology.

[14]  J. Bonneterre,et al.  Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data , 2014, Clinical Cancer Research.

[15]  Daniel Birnbaum,et al.  Genomic profiling of inflammatory breast cancer: a review. , 2014, Breast.

[16]  Rosette Lidereau,et al.  miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness , 2013, International journal of cancer.

[17]  Randa El-Zein,et al.  Genomic and expression analysis of microdissected inflammatory breast cancer , 2013, Breast Cancer Research and Treatment.

[18]  F. Bertucci,et al.  Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets , 2013, Clinical Cancer Research.

[19]  E. Wang,et al.  Global Profiling of Alternative Splicing Events and Gene Expression Regulated by hnRNPH/F , 2012, PloS one.

[20]  A. Angelucci,et al.  Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  C. Reddy,et al.  Modern outcomes of inflammatory breast cancer. , 2012, International Journal of Radiation Oncology, Biology, Physics.

[22]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[23]  Nicholas C. Flytzanis,et al.  An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.

[24]  G. Kristiansen,et al.  Old proteins – new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells , 2011, Acta physiologica.

[25]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Daniel Birnbaum,et al.  High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.

[27]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[28]  Patrick Pauwels,et al.  Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.

[29]  Seigo Nakamura,et al.  Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.

[30]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[31]  Pierre de la Grange,et al.  A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants , 2007, BMC Bioinformatics.

[32]  Didier Auboeuf,et al.  FAST DB: a website resource for the study of the expression regulation of human gene products , 2005, Nucleic acids research.

[33]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Elisabeth Remy,et al.  GeneANOVA-gene expression analysis of variance , 2002, Bioinform..

[35]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.